Daiichi Sankyo Company, Limited (TYO:4568)

Market Cap	4.70T -29.7%
Revenue (ttm)	2.12T +12.6%
Net Income	259.87B -12.1%
EPS	140.37 -9.9%
Shares Out	1.82B
PE Ratio	18.40
Forward PE	15.57
Dividend	100.00 (3.82%)
Ex-Dividend Date	Mar 30, 2026

Volume	2,298,100
Open	2,518.50
Previous Close	2,582.50
Day's Range	2,488.00 - 2,535.00
52-Week Range	2,443.00 - 4,178.00
Beta	-0.18
Analysts	Strong Buy
Price Target	4,352.35 (+72.61%)
Earnings Date	May 11, 2026

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1899
• Employees: 19,765
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4568

Financial Performance

In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 259.87 billion, a decrease of -12.13%.

Analyst Summary

According to 17 analysts, the average rating for 4568 stock is "Strong Buy." The 12-month stock price target is ¥4,352, which is an increase of 72.61% from the latest price.

Price Target

¥4,352

(72.61% upside)

Analyst Consensus: Strong Buy